PacBio (PACB)
Healthcare
Close on Nov 11, 2026 (from our latest article): $2.09
- Market value
- $654Mat the Nov 11 close
- Revenue growth
- +4%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- −89%12 months to Sep 30, 2026 (10-Q)
- Net debt
- $444Mat Sep 30, 2026
- Worst fall since listing
- −98.2%Feb 11, 2021 to May 27, 2025; not back to that high (−96.6% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names PacBio
Long-term fundamentals
Annual results for PacBio, FY2009–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $0.1M in FY2009 to $160M in FY2025.
Free cash flow was positive in 1 of the 17 years shown; FY2025: −$114M.
Margins
Margins are not charted: in FY2025 the operating loss (−$554M) was larger than revenue ($160M). The table has each year's figures.
Diluted share count
The diluted share count rose 71% from FY2020 to FY2025, to 300M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $160M | 29% | −346% | −$546M | −$111M | $3M | −$114M |
| FY2024 | $154M | 24% | −308% | −$310M | −$206M | $6M | −$212M |
| FY2023 | $201M | 26% | −167% | −$307M | −$259M | $9M | −$268M |
| FY2022 | $128M | 38% | −239% | −$314M | −$263M | $17M | −$280M |
| FY2021 | $131M | 45% | −161% | −$181M | −$111M | $6M | −$117M |
| FY2020 | $79M | 41% | −132% | $29M | $20M | $1M | $18M |
| FY2019 | $91M | 38% | −111% | −$84M | −$78M | $3M | −$81M |
| FY2018 | $79M | 32% | −128% | −$103M | −$66M | $2M | −$68M |
| FY2017 | $93M | 37% | −96% | −$92M | −$68M | $10M | −$78M |
| FY2016 | $91M | 49% | −79% | −$74M | −$68M | $8M | −$76M |
| FY2015 | $93M | 58% | −31% | −$32M | −$48M | $3M | −$51M |
| FY2014 | $61M | 39% | −104% | −$66M | −$51M | $2M | −$53M |
| FY2013 | $28M | 23% | −275% | −$79M | −$30M | $0.9M | −$31M |
| FY2012 | $26M | 4% | −363% | −$94M | −$77M | $2M | −$79M |
| FY2011 | $34M | 38% | −324% | −$109M | −$103M | $9M | −$112M |
| FY2010 | $2M | 100% | — | −$140M | −$122M | $5M | −$127M |
| FY2009 | $0.1M | 100% | — | −$88M | −$75M | $5M | −$80M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 300M | $280M | $645M | $42M | — | — |
| FY2024 | 288M | $390M | $647M | $71M | — | — |
| FY2023 | 254M | $727M | $893M | $72M | — | — |
| FY2022 | 225M | $842M | $899M | $79M | — | — |
| FY2021 | 204M | $1.2B | $898M | $73M | — | — |
| FY2020 | 175M | $339M | — | $18M | — | — |
| FY2019 | 153M | $49M | $16M | $16M | — | — |
| FY2018 | 135M | $104M | $15M | $23M | — | — |
| FY2017 | — | $63M | $14M | $20M | — | — |
| FY2016 | — | $72M | $16M | $20M | — | — |
| FY2015 | — | $82M | $15M | $14M | — | — |
| FY2014 | — | $101M | $14M | $10M | — | — |
| FY2013 | — | $113M | $13M | $10M | — | — |
| FY2012 | — | $101M | $3M | $10M | — | — |
| FY2011 | — | $177M | $3M | $12M | — | — |
| FY2010 | — | $284M | $3M | $10M | — | — |
| FY2009 | — | $89M | — | $4M | — | $0.0M |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 11, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | PACB | S&P 500 |
|---|---|---|
| 2019 | −30.5% | +31.5% |
| 2020 | +404.7% | +18.4% |
| 2021 | −21.1% | +28.7% |
| 2022 | −60.0% | −18.1% |
| 2023 | +19.9% | +26.3% |
| 2024 | −81.3% | +25.0% |
| 2025 | +2.2% | +17.9% |
| 2026 to date | −5.9% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- VCYT Veracyte Down 54.3%
- IRTC iRhythm Down 30.7%
- LEGN Legend Down 16%
- IBRX ImmunityBio Down 17.7%
- IDXX IDEXX Laboratories Up 21.8%
Questions about PacBio
- Why did PacBio stock fall on Nov 12, 2026?
- It isn't settled. At the last four quarters' average burn of $35.8 million, the $199.4 million PacBio had at Sep 30 would last into early 2028, the year it targets for breakeven, and the full $100 million stock program would add about two to three quarters (our calculation, not a forecast). PacBio expects burn to fall meaningfully in 2027; it has moved its breakeven date twice before. Read the article →